Pharmaceutical composition with anti-ischemic and antioxidant activity and method for preparing it |
|
|
IPC classes for russian patent Pharmaceutical composition with anti-ischemic and antioxidant activity and method for preparing it (RU 2545833):
|
FIELD: medicine. SUBSTANCE: invention refers to a pharmaceutical composition with anti-ischemic and antioxidant activity in the form of tablets or capsules, and a method for preparing it. The composition contains 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid in an amount of 40 to 80 wt %, an amino-containing compound and pharmaceutically acceptable excipients. The amino-containing compound is specified in a group of trometamol, methyl glucamine and L-lysine; 1 mole of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid is accounted for 0.05 to 0.25 mole of the above amino-containing compound. The composition also contains lactose, microcrystalline cellulose, calcium stearate and other pharmaceutically acceptable excipients. According to the method for preparing the composition, taking 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid and amino-containing compound in molar ratio 1:0.05 to 1:0.25, pre-mixing, moisturising with a aqueous or alcohol solution of a binding agent, adding pharmaceutically acceptable excipients in such an amount to provide the content of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid from 40 to 80 wt %, granulating the mixture, drying and producing tablets or capsules according to the known technique. EFFECT: implementing the above application. 6 cl, 7 tbl, 4 ex
|
Pharmaceutical preparation / 2542512
Present invention refers to pharmaceutical industry, namely to a preparation for treating an inflammatory condition related to ischemia. A pharmaceutical preparation for treating the internal inflammatory condition related to ischemia containing: a) normal saline containing at least 105 peripheral mononuclear cells (PMC) or their population per one ml, or b) supernatant of normal saline a), wherein normal saline a) is prepared by culturing the PMC or their population in normal saline free from PMC-proliferating or PMC-activating substances; the PMC or their population is cultured in the environment causing the pre- or intra-culture stress. Using the preparation for producing a therapeutic agent for treating the internal inflammatory condition related to ischemia. A method for preparing the pharmaceutical preparation.
Otamixaban for treating non-st elevation myocardial infarction in senior patients and patients suffering disturbed renal function / 2542455
Present group of inventions refers to medicine, namely cardiology, and concerns treating non-ST elevation myocardial infarction. That is ensured by administering (2R,3R)-2-(3-carbamimidoyl benzyl)-3-[4-(1-oxypyridinyl)benzoylamino]butyric acid methyl ester (otamixaban) or its pharmaceutically acceptable salt in a dose of 0.070 mg/kg - 0.14 mg/kg.
Herbal tea for prevention of primary ischemic stroke in patients with cerebrovascular disease / 2542423
Herbal tea has the hypolipidemic, antiaggregant, vasoprotective and adaptogenic action. The herbal tea contains common liquorice roots, blood-red hawthorn fruit, wild camomile blossom, blood-red hawthorn blossom, elevated part of meadow crane, elevated part of clump speedwell, clove tree flower buds, sweet flag rhizome, turmeric rhizome, anomalous peony root, common valerian rhizomes, elevated part of common sweet clover, common willow leaves, field caraway fruit, elevated part of tripartite bur-marigold, elevated part of common St. John's wort, elevated part of garden sage, meadowsweet blossom, elevated part of field mint, elevated part of cudweed in certain proportions. The above herbal tea extends the range of products for preventing primary ischemic stroke in the patients suffering cerebrovascular disease. It promotes mobilising all links of self-protection: immune protective, antioxidant and detoxification, neuroendocrine system.
Eluting stent with containers / 2541753
Invention refers to medicine, namely to developing expandable medical devices, particularly stents, and can be used for treating restenosis in a vessel lumen. A presented implantable medical device involves intraluminal frame (IF) comprising a number of openings. The IF has a tubular configuration and comprises a number of cylindrical sections connected by the number of connective elements. Each of the cylindrical sections of the IF is formed of a mesh of elongated braces connected by plastic pivots and peripheral braces. Different openings of the IF are filled with at least two various therapeutic agents. At least one therapeutic agent filling one of the openings is incorporated into poly(lactic-co-glycolic acid) (PLGA) matrix to control a release rate and a cumulative released dose of the therapeutic agent into the surrounding tissue.
Method for preparing therapeutic composition / 2541463
Invention refers to biotechnology, more specifically to agents for preparing a therapeutic composition of seashell, which can be used in gerontological practice for preventing the initial forms of atherosclerosis in elderly patients. A method for preparing the composition consists in producing an acid hydrolysate of conch shell meat, and an alkaline hydrolysate of mussels. The prepared alkaline and acidic hydrolysates are combined in volume ratio 10:1; pH is reduced to 6.4-6.6 with constant stirring, and the mixed hydrolysates are evaporated in the vacuum environment 0.65 kg s/cm2 at temperature 95-97°C to 20-25% on a dry matter basis.
Using 5?-androstane-3(,5,6(-triol for preparing neuroprotective drugs / 2541093
What is presented is using 5α-androstane -3β,5,6β-triol for preparing neuroprotective drugs.
Substance reducing cholesterol esterase activity / 2540518
Invention refers to medicine, pharmacology and biology. What is presented is a complex of tris-(2-hydroxyethyl)amine and bis-(2-methylphenoxyacetate)zinc [cinkatran or citrimin] of formula: (HOCH2CH2)3N·Zn(OOCCH2OC6H4CH3-2)2 as an agent reducing cholesterol esterase activity.
Method of treating patient with hypertrophic cardiomyopathy / 2540475
Method involves recovering DNA, detecting polymorphism of AGTR1 gene coding angiotensin II receptor type 1. That is followed by detecting polymorphism of ACE gene coding angiotensin converting enzyme; in case of having combinations of AC(AGTR1)/ID(ACE) or AA(AGTR1)/DD(ACE) genotypes detected, angiotensin II receptor blockers, in particular losartan 50mg twice a day are prescribed as a part of the complex therapy.
2-ethyl-6-methyl-3-hydroxypyridine dichloroacetate, its stable crystalline form and method of obtaining thereof / 2540070
Invention relates to novel substance - 2-ethyl-6-methyl-3-hydroxypyridine dichloroacetate of formula I ![]()
its stable crystalline form and method of obtaining thereof. Substance (I) possesses antiatherosclerotic, hypolipidemic, antihypoxic, nootropic, anxiolytic and adaptogenic action with low toxicity (LD50=30000 mg/kg, rats, intragastrically) and absence of hygroscopicity. Substance is obtained with interaction of equimolar quantities of 2-ethyl-6-methyl-3-hydroxypyridine and dichloroacetic acid in presence of solvent.
Method of treating atherosclerosis having anti-cytokine action / 2539377
Invention refers to medicine, namely to therapy, and concerns preventing and treating atherosclerosis. That is ensured by prescribing tablets or capsules with their active ingredients representing black elder blossom, marigold blossom and violet herb in certain proportions. Two tablets or two capsules are administered two times a day every 12 hours within the unlimited therapeutic course.
Method for producing agent possessing anti-inflammatory, diuretic and antioxidant activity / 2542493
Method for preparing an agent possessing anti-inflammatory, diuretic and antioxidant activity, involving milling Spiraea salicifolia shoots representing a mixture of leaves, blossom and shoots, extracting them three times by gradual maceration, mixing in infusing, filtering, condensing, separating, drying in the certain environment.
Antioxidant and membrane stabilising agent / 2540466
Invention refers to medicine and can be used as a hepatotrophic, lipotropic agent in gastroenterology, as well as for treating cardiac and cerebral atherosclerosis, in neurology in the lower extremity artery diseases (endarteritis). The agent contains tabletted powders of diisopropylammonium dichloroacetate, microcrystalline cellulose, lactose and excipients presented by Aerosil, Primogel and calcium stearyl fumarate.
6-methyl-5-morpholynomethyl-1-(thiethan-3-yl)pyrimidine-2,4(1h,3h)-dione, demonstrating antioxidant activity / 2539302
Invention relates to heterocyclic compound - 6-methyl-5-morpholynomethyl-1-(thiethan-3-yl)pyrimidine-2,4(1H,3H)-dione of formula 6-methyl-5-morpholynomethyl-1-(thiethan-3-yl)pyrimidine-2,4(1H,3H)-dione of formula: ![]()
.
Pharmaceutical composition for treating gastroduodenal ulcer, possessing immunomodulatory, antiviral, antibacterial, anti-inflammatory, antioxidant and regenerative effect in form of tablets, capsules or gel / 2538697
Invention refers to medicine, and concerns a pharmaceutical composition for treating gastroduodenal ulcer in the form of tablets, capsules or gel, containing therapeutic agents and a consistency base applicable for each dosage, wherein the therapeutic agents are as follows: recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; antiseptics; amino acids specified in a group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; and antioxidants specified in a group: beta-carotene, vitamin C, vitamin E.
Pharmaceutical composition for preventing and treating infectious-inflammatory diseases of various origins by oromucosal administration / 2538433
Invention refers to medicine, and concerns a pharmaceutical composition in the form of tablets for oromucosal administration in treating infectious-inflammatory oropharyngeal diseases. The composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; amino acid specified in a group: arginine, histidine, glycine, glutathione, lysine, methionine, cysteine; an antiseptic, a preserving agent, flavours specified in a group: tea tree oil, eucalyptus leaf oil, mint leaf oil and a consistence base.
Biologically active food additive / 2538220
Biologically active food additive strengthening the organism adaptive power and body defences and having anti-inflammatory and antioxidant activity contains vegetal origin components represented by a complex extract of devil's-club root, Rhaponticum carthamoides root, Hedysarum neglectum Ledeb root, celery roots and leaves, rhodiola rosea root, Japanese angelica tree roots, boschniakia rossica roots, Hungarian sainfoin herb, magnolia-vine fruits; additionally the additive contains chitosan, trepang fermentative hydrolysate, ascorbic acid, taurine, glutathione, nicotinamide, vitamin B1, vitamin B2, vitamin B6, vitamin B12, folic acid, anhydrous calcium chloride, magnesium chloride, zinc chloride, bee honey at preset ingredients ratio.
Method of preventing cerebral form of radiation sickness / 2537170
Invention relates to medical radiology and can be used for prevention of cerebral form of acute radiation sickness. Claimed is application of officinal drug pyrazinamide as medication for prevention of cerebral form of acute radiation sickness. Pyrazinamide has been used for treating tuberculosis.
Composition with antioxidant and antibacterial activity / 2535140
Invention refers to medicine and represents a composition possessing the antioxidant and antibacterial activity and containing lithium ascorbate, differing by the fact that it additionally contains lithium benzoate in the following proportions, wt %: lithium ascorbate - 50; lithium benzoate - 50.
Method for increasing antitoxic body function in healthy individuals occupied in chemical load environment / 2535066
Method for increasing the antitoxic body function in healthy individuals occupied in the chemical load environment involving administering an antioxidant water containing carrot juice, cod liver oil, olive oil, honey; the water is taken daily before the working shift for 10 days.
Sublingual form of 6-methyl-2-ethyl-3-hydroxypyridine and using it as agent possessing stimulating, anorectic, antidepressant, anxiolytic, antihypoxic, antiamnestic (nootropic), and antialcohol activity / 2527342
What is described is using a pharmaceutical composition in the form of an orally disintegrated tablet containing 6-methyl-2-ethyl-3-hydroxypyridine succinate as an active substance and crospovidone as a disintegrating agent in ratio 2:1 respectively, as a motor stimulating and anorectic agent.
Prolonged antihypertension pharmaceutical composition and method for preparing it / 2543637
Invention refers to the chemical-pharmaceutical industry and represents a composition in the form of a gelatine capsule possessing the antihypertensive action, containing lisinopril dihydrate granules and verapamil hydrochloride tablets in a ratio of 1:5 to 1:20.